<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Schmieder, Roland E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Renewed Focus on RH in the RDN World</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">28-30</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the renewed focus on treatment-resistant hypertension (RH), which has been sparked by the interest in catheter renal denervation and the somewhat disappointing results with this interventional approach in the SYMPLICITY HTN trial program.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>